The company has identified a novel target to prevent/reverse metabolic liver disease NASH. NASH patients have a high risk of morbidity/mortality due to progression into cirrhosis, liver failure, and hepatocellular carcinoma (HCC). To date, no pharmacological treatment is available for NASH and liver transplantation is the only option for people living with advanced NASH.
Impact: Reduce patient suffering/mortality and healthcare expenses.
CEO: Prof. Margit MahlapuuGUV Contact: Lorna Fletcher